Pharmacokinetics, Metabolism, Excretion and Safety of Iruplinalkib (WX-0593), a Novel ALK Inhibitor, in Healthy Subjects: a Phase I Human Radiolabeled Mass Balance Study.
Expert Opinion on Investigational Drugs（2024）
关键词
ALK inhibitors,covalent protein binding,iruplinalkib,mass balance,metabolite profiling,NSCLC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要